The Patent Landscape of Nanomedicines
Main Article Content
Abstract
N/A
Article Details
How to Cite
BOWMAN, Diana; MARINO, Antonio D; SYLVESTER, Douglas J.
The Patent Landscape of Nanomedicines.
Medical Research Archives, [S.l.], v. 5, n. Issue 9, sep. 2017.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/1470>. Date accessed: 25 apr. 2024.
Section
Research Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
[1] Grand View Research 2017. Nanomedicine Market Size Worth $350.8 Billion By 2025 | CAGR: 11.2%. Available at: http://www.grandviewresearch.com/press-release/global-nanomedicine-market
[2] Bowman, DM & Gatof, J. (2015). Reviewing the regulatory barriers for nanomedicine: global questions and challenges. Nanomedicine, 10(21), 3275-3286.
[3] See Elan Pharma Int'l v. Abraxis Bioscience, No. 06-438 GMS, 2008 U.S. Dist. LEXIS 125886 (D. Del. June 16, 2008).
[4] Bolado, C. 2011. Celgene Strikes $78M Deal In Elan Abraxane IP Suit, Law360, 24 February. Available at: https://www.law360.com/articles/228152.
[5] Bowman, DM, Sylvester, DJ and Marino, A. 2017. ‘Returning to the Patent Landscapes for Nanotechnology; Assessing the garden that it has grown into,’ in Sarah J Hurst and Emily Day (eds), Biomedical Nanotechnology: Methods and Protocols, New York: Springer, pp.315-448.
[6] Tinkle, S, McNeil, SE, Mühlebach, S, Bawa, R, Borchard, G, Barenholz, YC, ... & Desai, N. 2014. Nanomedicines: addressing the scientific and regulatory gap. Annals of the New York Academy of Sciences, 1313(1), 35-56.
[7] DeVol, RC, et al. 2011. The Global Biomedical Industry: Preserving U.S. Leadership, Milken Institute, September. Available at:
http://assets1b.milkeninstitute.org/assets/Publication/ResearchReport/PDF/CASMIFullReport.pdf.
[8] U.S. Constitution, article I, § 8, clause
[9] Heller, MA and Eisenberg, RS 1998. Can patents deter innovation? The anticommons in biomedical research. Science, 280(5364), 698-701.
[10] ETC Group 2005. Nanotech’s “Second Nature” Patents: Implications for the Global South, June. Available at: http://www.etcgroup.org/sites/www.etcgroup.org/files/publication/54/02/com8788specialpnanomar-jun05eng.pdf.
[11] Initiative for Medicines Access and Knowledge 2013. Patent Landscape Report for Pegylated Interferon Alfa 2A and 2B, February. Available at: http://static1.1.sqspcdn.com/static/f/129694/21983308/1361387069633/I-MAK+Patent+Landscape+for
[12] Enzon Pharmaceuticals 2001. Enzon Announces Schering-Plough In-Licensing Agreement with Roche Resolving Peginterferon Patent Disputes, 13 August. Available at: http://investor.enzon.com/releasedetail.cfm?ReleaseID=138770.
[13] Romero‐Gómez, M, Planas, R, Ampuero, J, Sola, R, García‐Samaniego, J, Diago, M, ... and Turnes, J. 2013. Meta‐analysis: pegylated interferon α‐2a achieves higher early virological responses than α‐2b in chronic hepatitis C. Alimentary pharmacology & therapeutics, 37(11), 1065-1073.
[14] Mossof, A. 2011. The Rise and Fall of the First American Patent Thicket: The Sewing Machine War of the 1850s’. Arizona Law Review, 53, 165.
[15] Cutler, M. 2015. 3 Years Of IPR: A Look at The Stats, Law360, 9 October. Available at: https://www.law360.com/articles/699867/3-years-of-ipr-a-look-at-the-stats.
[16] Brachmann, S. 2017. PTAB ends Kyle Bass IPRs targeting Acorda patents on Ampyra MS treatment with no findings of obviousness, IP Watchdog, 14 March. Available at: http://www.ipwatchdog.com/2017/03/14/ptab-ends-iprs-targeting-patents-acordas-ampyra-ms-treatment/id=79489/
[17] Quinn, G. 2017. Patent Reform 2017: Changes coming from the Judiciary, Legislative and Executive Branches, IP Watchdog. Available at: http://www.ipwatchdog.com/2017/02/12/patent-reform-2017/id=78189/
[2] Bowman, DM & Gatof, J. (2015). Reviewing the regulatory barriers for nanomedicine: global questions and challenges. Nanomedicine, 10(21), 3275-3286.
[3] See Elan Pharma Int'l v. Abraxis Bioscience, No. 06-438 GMS, 2008 U.S. Dist. LEXIS 125886 (D. Del. June 16, 2008).
[4] Bolado, C. 2011. Celgene Strikes $78M Deal In Elan Abraxane IP Suit, Law360, 24 February. Available at: https://www.law360.com/articles/228152.
[5] Bowman, DM, Sylvester, DJ and Marino, A. 2017. ‘Returning to the Patent Landscapes for Nanotechnology; Assessing the garden that it has grown into,’ in Sarah J Hurst and Emily Day (eds), Biomedical Nanotechnology: Methods and Protocols, New York: Springer, pp.315-448.
[6] Tinkle, S, McNeil, SE, Mühlebach, S, Bawa, R, Borchard, G, Barenholz, YC, ... & Desai, N. 2014. Nanomedicines: addressing the scientific and regulatory gap. Annals of the New York Academy of Sciences, 1313(1), 35-56.
[7] DeVol, RC, et al. 2011. The Global Biomedical Industry: Preserving U.S. Leadership, Milken Institute, September. Available at:
http://assets1b.milkeninstitute.org/assets/Publication/ResearchReport/PDF/CASMIFullReport.pdf.
[8] U.S. Constitution, article I, § 8, clause
[9] Heller, MA and Eisenberg, RS 1998. Can patents deter innovation? The anticommons in biomedical research. Science, 280(5364), 698-701.
[10] ETC Group 2005. Nanotech’s “Second Nature” Patents: Implications for the Global South, June. Available at: http://www.etcgroup.org/sites/www.etcgroup.org/files/publication/54/02/com8788specialpnanomar-jun05eng.pdf.
[11] Initiative for Medicines Access and Knowledge 2013. Patent Landscape Report for Pegylated Interferon Alfa 2A and 2B, February. Available at: http://static1.1.sqspcdn.com/static/f/129694/21983308/1361387069633/I-MAK+Patent+Landscape+for
[12] Enzon Pharmaceuticals 2001. Enzon Announces Schering-Plough In-Licensing Agreement with Roche Resolving Peginterferon Patent Disputes, 13 August. Available at: http://investor.enzon.com/releasedetail.cfm?ReleaseID=138770.
[13] Romero‐Gómez, M, Planas, R, Ampuero, J, Sola, R, García‐Samaniego, J, Diago, M, ... and Turnes, J. 2013. Meta‐analysis: pegylated interferon α‐2a achieves higher early virological responses than α‐2b in chronic hepatitis C. Alimentary pharmacology & therapeutics, 37(11), 1065-1073.
[14] Mossof, A. 2011. The Rise and Fall of the First American Patent Thicket: The Sewing Machine War of the 1850s’. Arizona Law Review, 53, 165.
[15] Cutler, M. 2015. 3 Years Of IPR: A Look at The Stats, Law360, 9 October. Available at: https://www.law360.com/articles/699867/3-years-of-ipr-a-look-at-the-stats.
[16] Brachmann, S. 2017. PTAB ends Kyle Bass IPRs targeting Acorda patents on Ampyra MS treatment with no findings of obviousness, IP Watchdog, 14 March. Available at: http://www.ipwatchdog.com/2017/03/14/ptab-ends-iprs-targeting-patents-acordas-ampyra-ms-treatment/id=79489/
[17] Quinn, G. 2017. Patent Reform 2017: Changes coming from the Judiciary, Legislative and Executive Branches, IP Watchdog. Available at: http://www.ipwatchdog.com/2017/02/12/patent-reform-2017/id=78189/